Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Heo, Jang Won ^a   Kim, Jin Hyoung ^b   Cho, Chang Sik ^b   Jun, Hyoung Oh ^b   Kim, Dong Hun ^c   Yu, Young Suk ^a,b   Kim, Jeong Hun ^a,b,d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE A; SHANK2 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; MAPK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NERVE PROTEIN; NEUROFILAMENT PROTEIN; PRIMER DNA; SHANK2 PROTEIN, HUMAN; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEUROFILAMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG ANTAGONISM; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; RECEPTOR, TRKA; RETINOBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863351281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033456     Document Type: Article

References (32)

1. Ferrara N, Henzel WJ, (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
2. Folkman J, (2006) Angiogenesis. Annu Rev Med 57: 1-18.
3. Carmeliet P, Storkebaum E, (2002) Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 13: 39-53.
4. Kim JH, Kim JH, Park JA, Lee SW, Kim WJ, et al. (2006) Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 39: 339-345.
5. Jo DH, Kim JH, Kim JH, (2010) How to overcome retinal neuropathy: The fight against angiogenesis-related blindness. Arch Pharm Res 10: 1557-1565.
6. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, et al. (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 99: 11946-11950.
7. Sun FY, Guo X, (2005) Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J Neurosci Res 79: 180-184.
8. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M, (2007) Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 52: S3-19.
9. Adamis AP, Shima DT, (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25: 111-118.
10. Andreoli CM, Miller JW, (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18: 502-508.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372.
13. Spaide RF, Fisher YL, (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26: 275-278.
14. Manzano RP, Peyman GA, Khan P, Kivilcim M, (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257-261.
15. Iriyama A, Chen YN, Tamaki Y, Yanagi Y, (2007) Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91: 1230-1233.
16. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U, (2008) Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28: 46-55.
17. Kim JH, Kim C, Kim JH, Lee BJ, Yu YS, et al. (2008) Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 29: 1131-1135.
18. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, et al. (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773-1781.
19. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, et al. (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995-1002.
20. Kim JH, Kim JH, Kim DH, Cho CS, Jun HO, et al. (2009) Neurotrophin receptors TrkA and TrkB in retinoblastoma are differentially expressed depending on cellular differentiation. Tumour Biol 30: 233-241.
21. Kim JH, Kim JH, Yang E, Park JH, Yu YS, et al. (2009) Shank 2 expression coincides with neuronal differentiation in the developing retina. Exp Mol Med 41: 236-242.
22. Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ, et al. (2007) Establishment and characterization of a novel, spontaneously immortalized retinoblastoma cell line with adherent growth. Int J Oncol 31: 585-592.
23. Kim JH, Kim JH, Cho CS, Jun HO, Kim DH, et al. (2010) Differential roles of matrix metalloproteinase-9 and-2, depending on proliferation or differentiation of retinoblastoma cells. Invest Ophthalmol Vis Sci 51: 1783-1788.
24. Akil H, Perraud A, Mélin C, Jauberteau MO, Mathonnet M, (2011) Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One 6: e25097.
25. Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ, et al. (2009) Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration. Invest Ophthalmol Vis Sci 50: 1819-1823.
26. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
27. Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, et al. (2010) Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology 117: 1974-1981.
28. Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, et al. (2010) Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture. Curr Diabetes Rev 6: 313-322.
29. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2008) Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One 3: e3554.
30. Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, et al. (2010) Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 224: 262-272.
31. Louissaint A Jr, Rao S, Leventhal C, Goldman SA, (2002) Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34: 945-960.
32. Nork TM, Schwartz TL, Doshi HM, Millecchia LL, (1995) Retinoblastoma; Cell of origin. Arch Ophthalmol 113: 791-802.